SI1892298T1 - Cepivo proti streptokokni C5a peptidazi - Google Patents

Cepivo proti streptokokni C5a peptidazi

Info

Publication number
SI1892298T1
SI1892298T1 SI9931054T SI9931054T SI1892298T1 SI 1892298 T1 SI1892298 T1 SI 1892298T1 SI 9931054 T SI9931054 T SI 9931054T SI 9931054 T SI9931054 T SI 9931054T SI 1892298 T1 SI1892298 T1 SI 1892298T1
Authority
SI
Slovenia
Prior art keywords
streptococcal
scp
disclosed
infection
peptidase
Prior art date
Application number
SI9931054T
Other languages
English (en)
Inventor
Paul Patrick Cleary
Deborah K Stafslien
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of SI1892298T1 publication Critical patent/SI1892298T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Exposure Control For Cameras (AREA)
SI9931054T 1998-12-07 1999-12-03 Cepivo proti streptokokni C5a peptidazi SI1892298T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/206,898 US6355255B1 (en) 1998-12-07 1998-12-07 Streptococcal C5a peptidase vaccine
EP07015995A EP1892298B1 (en) 1998-12-07 1999-12-03 Streptococcal C5a peptidase vaccine

Publications (1)

Publication Number Publication Date
SI1892298T1 true SI1892298T1 (sl) 2011-08-31

Family

ID=43662233

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9931070T SI2308981T1 (sl) 1998-12-07 1999-12-03 Streptokokno cepivo s C5A peptidazo
SI9931054T SI1892298T1 (sl) 1998-12-07 1999-12-03 Cepivo proti streptokokni C5a peptidazi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI9931070T SI2308981T1 (sl) 1998-12-07 1999-12-03 Streptokokno cepivo s C5A peptidazo

Country Status (18)

Country Link
US (4) US6355255B1 (sl)
EP (3) EP1137785B8 (sl)
JP (2) JP5122703B2 (sl)
KR (1) KR100777502B1 (sl)
CN (2) CN1679929B (sl)
AT (2) ATE503017T1 (sl)
AU (2) AU779085B2 (sl)
BR (1) BRPI9915988B8 (sl)
CA (1) CA2354508C (sl)
CY (1) CY1106983T1 (sl)
DE (2) DE69943305D1 (sl)
DK (3) DK1137785T3 (sl)
ES (3) ES2363446T3 (sl)
IL (2) IL143289A0 (sl)
MX (1) MXPA01005757A (sl)
PT (3) PT1892298E (sl)
SI (2) SI2308981T1 (sl)
WO (1) WO2000034487A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
WO2004094468A2 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
AU2005302269B2 (en) 2004-11-01 2011-05-19 The Brigham And Women's Hospital, Inc. Modified streptococcal polysaccharides and uses thereof
GB2428006A (en) * 2005-07-07 2007-01-17 Jevgenis Morov AMI-3 vaccine comprising group A Streptococcus pyogenes bacteria
US7596254B2 (en) * 2006-03-17 2009-09-29 William Marsh Rice University Intra-operative 3-D reconstruction of bone cement boli using X-rays
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2654269C (en) * 2006-06-23 2015-09-22 Danisco Us Inc. Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
US20080311129A1 (en) * 2006-11-02 2008-12-18 Camas Incorporated Adherence inhibitor directed to and method of making and using
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2586418T3 (es) * 2007-04-16 2016-10-14 Minervax Aps Vacuna de proteína de fusión
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
DK2356135T3 (en) 2008-11-05 2017-12-04 Wyeth Llc IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102746388B (zh) * 2012-07-02 2014-06-25 中山大学 一种链球菌保护性抗原C5a及其制备方法
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
KR101775093B1 (ko) 2016-05-31 2017-09-19 그린코스 주식회사 베타인살리실레이트와 폴리에틸렌글리콜을 포함하는 각질 용해 화장품 조성물, 그 제조 방법, 및 이를 포함하는 화장품
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN106822885B (zh) * 2017-02-16 2020-06-30 清华大学 肺炎链球菌疫苗
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
CN109045292A (zh) * 2018-11-08 2018-12-21 山东大学 一种a群链球菌寡糖蛋白缀合物及其制备方法与应用
KR102165688B1 (ko) 2020-04-03 2020-10-14 주식회사 퀀타매트릭스 그람 양성균 배양용 배양액
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) * 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
NZ191327A (en) * 1978-08-24 1981-07-13 W B Martin Pasteurellosis vaccine comprising antigenic material derived from the a1 and a2 serotypes of pasteurella haemolytica
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US4863159A (en) 1988-03-25 1989-09-05 Morrison Molded Fiber Glass Company Apparatus for use in the exercise of the human body
EP0365646B1 (en) 1988-03-25 1996-05-08 The Rockefeller University Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
DK0542869T3 (da) 1990-07-31 1996-02-05 Genentech Inc Vævsplasminogenaktivatorvarianter med nedsat udskillelse
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
WO1993014198A1 (en) 1992-01-08 1993-07-22 The Rockefeller University Multifunctional surface protein of streptococci
ATE228565T1 (de) 1992-03-09 2002-12-15 Univ California Nukleinsäure, expressionsvektor und zusammensetzungen zur identifizierung und herstellung von rekombinanten sialyltransferasen
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
IL106922A (en) 1992-09-14 1998-08-16 Novartis Ag Complex materials with one or more wettable surfaces and a process for their preparation
IL107026A0 (en) 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
IL107025A0 (en) 1992-09-16 1993-12-28 Univ Tennessee Res Corp Recombinant multivalent m protein vaccine
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5618129A (en) 1995-03-13 1997-04-08 Paragon Electric Company, Inc. Snap-engaging mounting plate
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist

Also Published As

Publication number Publication date
US8440205B2 (en) 2013-05-14
EP2308981B1 (en) 2013-02-13
BRPI9915988B8 (pt) 2021-05-25
US20050136068A1 (en) 2005-06-23
ES2293745T3 (es) 2008-03-16
DE69936877D1 (de) 2007-09-27
PT2308981E (pt) 2013-02-21
PT1137785E (pt) 2007-10-22
EP1137785B8 (en) 2007-11-21
CN1329669A (zh) 2002-01-02
IL143289A0 (en) 2002-04-21
EP2308981A1 (en) 2011-04-13
CY1106983T1 (el) 2012-09-26
EP1137785B1 (en) 2007-08-15
BR9915988A (pt) 2001-09-04
US20060153879A1 (en) 2006-07-13
CN1679929B (zh) 2012-09-26
DE69943305D1 (de) 2011-05-05
AU2166500A (en) 2000-06-26
MXPA01005757A (es) 2002-04-24
ES2363446T3 (es) 2011-08-04
PT1892298E (pt) 2011-06-01
SI2308981T1 (sl) 2013-04-30
US7635483B2 (en) 2009-12-22
EP1137785A1 (en) 2001-10-04
WO2000034487A1 (en) 2000-06-15
JP2012072153A (ja) 2012-04-12
KR20010082326A (ko) 2001-08-29
CN100389198C (zh) 2008-05-21
CN1679929A (zh) 2005-10-12
DE69936877T2 (de) 2008-04-30
DK1137785T3 (da) 2007-12-10
CA2354508C (en) 2011-02-01
EP1892298A1 (en) 2008-02-27
ATE503017T1 (de) 2011-04-15
US6951653B2 (en) 2005-10-04
IL143289A (en) 2011-11-30
AU2004231164B2 (en) 2008-05-01
AU779085B2 (en) 2005-01-06
AU2004231164A1 (en) 2004-12-09
US6355255B1 (en) 2002-03-12
BRPI9915988B1 (pt) 2015-08-18
ES2401998T3 (es) 2013-04-26
ATE370237T1 (de) 2007-09-15
DK1892298T3 (da) 2011-06-14
US20040062777A1 (en) 2004-04-01
DK2308981T3 (da) 2013-05-13
CA2354508A1 (en) 2000-06-15
JP2002531584A (ja) 2002-09-24
JP5122703B2 (ja) 2013-01-16
EP1892298B1 (en) 2011-03-23
KR100777502B1 (ko) 2007-11-16

Similar Documents

Publication Publication Date Title
IL143289A0 (en) Streptococcal c5a peptidase vaccine
PT877624E (pt) Vacina de c5a peptidase estreptococica
EP2050464A3 (en) Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
HK1043943A1 (zh) 肺炎鏈球菌蛋白質和疫苗
DK0652758T3 (da) Diferitoxin-vacciner
PL304419A1 (en) Urease based vaccine against heliobacter infections
NZ507717A (en) Derivatives of pneumococcal choline binding proteins for vaccines
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
PL303482A1 (en) Vaccine against infection with streptococcus suis, streptococcus suis polypeptide and method of preparing such vaccine
TW275632B (sl)
AU2015095A (en) Mucosal administration of pneumococcal antigens
IL129366A0 (en) Helicobacter pylori live vaccine
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
MY153646A (en) A vaccine protecting against pig haemophilosis.
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.